Dr. Stacy L. Cooper
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
600 N Wolfe St
Baltimore, MD 21287
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
MD license D74065
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $1,784 in total to this clinician.
| Syndax Pharmaceuticals, Inc. | $1,784 |
|---|
| Consulting Fee | $1,648 |
|---|---|
| Food and Beverage | $136 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. Sep 16, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $1,648 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $110,212 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
E.r. Squibb & Sons, L.l.c. · Terminated · NCT05255601 - A phase 1 2 trial of glofitamab with chemotherapy in pediatric patients with r r b nhl
Genentech, Inc. - A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B Cell Non Hod…
Kite Pharma, Inc. - A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic leukemia ALL who are minimal residual disease MRD positive at end of consolidation EOC therapy
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.